Glenmark Rolls Out World-First COPD Nebulized Triple Therapy

Glenmark Pharmaceuticals has launched the world’s first nebulized triple therapy for COPD, marking a major step forward in respiratory care.

The new products — Nebzmart GFB Smartules and Glenmark Airz FB Smartules — blend Glycopyrronium, Formoterol, and Budesonide into a single, easy nebulized dose.

This combined approach targets airway blockage, inflammation, and worsening lung function, offering relief to patients who struggle with MDIs or DPIs.

The arrival of this nebulized triple therapy reflects Glenmark’s push to bring simpler and more effective options to people living with chronic lung disease.

Also Read: Bridging Collaboration Gaps to Boost India's Pharma Discovery

"At Glenmark, innovation is about reimagining and redefining how therapies reach patients. With Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized triple therapy for COPD, we are transforming respiratory care,” said Alok Malik, President & Business Head, India Formulations, Glenmark Pharmaceuticals.

Clinical studies in India showed fast improvement in lung function and stronger control of breathlessness, with a safety profile that remained well-tolerated across patients. This gives doctors a new option for stable, consistent dosing without the complexity of multiple devices.

“This launch represents a significant advancement in the management of COPD and demonstrates our focus in strengthening global respiratory leadership,” said Dr Monika Tandon, Global Head of Clinical Development, Glenmark Pharmaceuticals.

Glenmark continues to expand its global footprint across branded, generics, and OTC therapies, supported by 11 manufacturing sites across four continents and operations in more than 80 countries. The company remains focused on respiratory, dermatology, and oncology as core therapeutic areas.